The US-EU pharma tariff cap has been finalized at 15%, impacting manufacturing, supply chain, and quality and promoting ...

Sanofi has received orphan designation from the EMA for rilzabrutinib, a reversible covalent BTK inhibitor, to treat IgG4-RD.

EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...

The company plans to launch the first version of its AI Advocate tool, aimed at helping patients manage and guide their ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

An HHS task force responsible for oversight of childhood shots that was disbanded in 1998 is coming back. The Task Force on ...

Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.

AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...